Board of Directors

Bruce W. Kovacs, MD

bruce_kovacsBruce is the founder of Afecta and inventor of several of our core technologies. He has held senior executive management positions at the University of Southern California’s Keck School of Medicine and University Healthcare Management, Inc., a national healthcare services company. In addition to co-founding GenePrints, a company that pioneered the use of DNA for purposes of human identification and disease diagnosis, he became a nationally recognized expert in human molecular genetics and received board certification in several medical specialties, including Clinical Molecular Genetics and OB/GYN. Dr. Kovacs has authored numerous papers and book chapters and is an inventor on several patents. He has been an invited speaker at many national and international conferences focused on molecular genetics, clinical medicine, and pharmacogenomics. Dr. Kovacs received his M.D. from the Keck School of Medicine at the University of Southern California and was a Clinical Professor and Director of the Molecular & Cytogenetics Laboratory at USC for over 20 years.

Alan Lewis, PhD

alan_lewisDr. Lewis has 37 years of experience as an executive in the life science industry. He spent 15 years at the pharmaceutical company Wyeth-Ayerst, where he was Vice President of Research, leading 550 scientists in translational research efforts including areas of diabetes, CNS, cardiovascular, inflammatory, allergy, and bone metabolism diseases. He served as CEO of Signal Pharmaceuticals, a drug development company that he successfully merged with Celgene and became President of Celgene’s research division in San Diego. Dr. Lewis earned his PhD from University of Wales, Cardiff and was a research fellow at University of Guelph, Canada and a research fellow at Yale School of Medicine. He is the author of 120 manuscripts and the editor of 7 books.

Woody Bryan, PhD

bryan_woodyDr. Bryan is currently SVP of Business Development at Sucampo Pharmaceuticals. He previously served as SVP of Business Development at Lupin Pharmaceuticals, VP of Business Development, Licensing at Supernus Pharmaceuticals, and VP of Business Development for Shire Laboratories Inc. Dr. Bryan was also Director of Business Development for Pharmaceutics and Clinical Supply Manufacturing for AAI and he began his career with Schering-Plough in Pharmaceutics and Formulation Development. He received his B.S. in Zoology from Clemson University, Ph.D. in Pharmaceutics from the Medical University of South Carolina in 1991, and an Executive Management Certificate from the University of North Carolina Kenan-Flagler Business School in 1999.

Peter Blaisdell, PhD

Dr. Blaisdell is currently a member of the screening committee for the Southern California Biomedical Council and a member of the scientific advisory board at Meditope. In his previous role, he was the Executive Director of Global Study Management at Amgen. He joined Amgen in 1998 supporting clinical research programs in infectious disease and nephrology and supporting the design and conduct of global cardiovascular and nephrology outcomes trials, successfully executing international phase 2 and 3 trials in support of filings, as well as phase 4 trials providing post-marketing support for a variety of therapies. Before joining Amgen, Dr. Blaisdell was a Senior Project Manager at Quintiles where he coordinated cross-functional teams in support of phase 2 - 4 trials for biotech and large pharma sponsors across a diverse range of therapeutic areas. He has contributed to cross-industry initiatives to expand the demographic diversity of trial enrollment and to foster improved outreach to patient advocacy groups. In addition, Dr. Blaisdell has authored both basic research publications and business management articles focusing on the bio/pharma industry and has taught graduate business classes on research management in MBA programs. He holds a Ph.D. in Biochemistry from the University of Minnesota, where he also conducted post-doctoral research in microbiology. He has a BS from the University of Michigan.

Ann Deren-Lewis, MBA

Ann Deren-Lewis has a proven track record in marketing in pharmaceutical and medical devices in these key therapeutic areas: aesthetics, cosmeceuticals (beauty brands), medical dermatology, and consumer products. Her clients include Johnson and Johnson, Pfizer, BioPhotas, and VI Aesthetics, among others. She is also the Chief Operating Officer for Mind and Body Research, which develops international licensing programs to provide turnkey assistance with operations and support for distributors in the pain and tissue discomfort arena. She has formulated and created the first product Demand Relief™ for the organization. Prior to these roles, she held senior executive positions with ChromaDex, Merz, Stiefel Labs (GSK), Johnson and Johnson, Genentech, and Amgen. In 2002, she was one of the original non-dermatologists invited to become a member of the American Academy of Dermatology, where she remains a member in good standing. Ann holds an MBA from Duke University, Fuqua School of Business and a bachelor of science degree in accounting from the University of North Carolina-Wilmington.